Biomm S.A. (BVMF:BIOM3)
Brazil flag Brazil · Delayed Price · Currency is BRL
7.54
+0.19 (2.59%)
Apr 28, 2026, 5:05 PM GMT-3

Biomm Company Description

Biomm S.A. operates as a biotechnology company in Brazil.

The company offers insulin products for the treatment of diabetes, including AFREZZA, a human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; Lifepen G, a reusable insulin injection pen; and Biopemm, a reusable insulin delivery device for diabetic patients.

It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the treatment of deep vein thrombosis and pulmonary embolism, unstable angina, and acute myocardial infarction; and RANIVISIO for treating vision problems related to abnormal blood vessel growth or fluid buildup in the retina.

The company was incorporated in 2001 and is based in Nova Lima, Brazil.

Biomm S.A.
CountryBrazil
Founded2001
IndustryBiotechnology
SectorHealthcare
Employees130
CEOGuilherme Maradei

Contact Details

Address:
705 – Lagoa dos Ingleses
Nova Lima, MG 34018-000
Brazil
Phone55 31 3299 1000
Websitebiomm.com

Stock Details

Ticker SymbolBIOM3
ExchangeBrazil Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyBRL
ISIN NumberBRBIOMACNOR2
SIC Code2836

Key Executives

NamePosition
Guilherme MaradeiChief Executive Officer and Member of Executive Board
Marcelo Sáfadi AlvaresChief Financial Officer and IR
Francisco Carlos Marques de FreitasDirector of Technology and Member of the Executive Board
Francisco Rafael Costa Jr.Commercial Director and Member of Executive Board
Luciano da Silva MachadoOperations Director and Member of Executive Board
Nayara Rodrigues de Souza CruzAccountant